{"id":"NCT01814748","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)","officialTitle":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05-03","primaryCompletion":"2015-09-14","completion":"2015-09-14","firstPosted":"2013-03-20","resultsPosted":"2016-07-18","lastUpdate":"2018-09-10"},"enrollment":203,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Omarigliptin","otherNames":["MK-3102"]},{"type":"DRUG","name":"Placebo to omarigliptin","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":["Fortamet®","Glucophage®","Glucophage® XR","Glumetza®","Riomet®","Metgluco®","Glycoran®"]}],"arms":[{"label":"Omarigliptin 25 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will examine the safety and efficacy of once-weekly omarigliptin in participants 18 to \\<45 years of age with Type 2 diabetes mellitus and inadequate glycemic control. The study hypothesis is that treatment with omarigliptin compared with placebo provides greater reduction in hemoglobin A1c (A1C) in participants after 24 weeks.","primaryOutcome":{"measure":"Change From Baseline in A1C at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Omarigliptin 25 mg","deltaMin":-0.33,"sd":null},{"arm":"Placebo","deltaMin":-0.45,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.535"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":19},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28923291"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":102},"commonTop":["Headache","Nausea"]}}